文献速递淋巴瘤造血干细胞移植与细胞治疗

双特异性抗体暴露后异基因造血干细胞移植作为B细胞淋巴瘤巩固治疗的GETH-TC研究

Allogeneic HCT as consolidation in B-cell lymphomas after exposure to bispecific antibodies: a GETH-TC study.
PubMed 文献 · Blood Adv · 2026-01-01

该国际回顾性研究比较47例双特异性抗体暴露后首次接受异基因造血干细胞移植的复发/难治B细胞非霍奇金淋巴瘤成人患者与101例历史未暴露队列。经IPTW和PSM校正后,2年非复发死亡率无显著差异,暴露组累积复发 incidence 在IPTW中显著降低,大B细胞淋巴瘤亚组中复发差异一致且PFS在IPTW中改善。结论认为既往双特异性抗体暴露不损害移植安全性,可能与更好的疾病控制相关。

要点

  • 双特异性抗体暴露后移植的2年非复发死亡率与未暴露队列无显著差异。
  • IPTW分析显示暴露组累积复发率显著更低,大B细胞淋巴瘤亚组结果一致。
  • 总生存、GVHD、无GVHD无复发生存和植入情况两组相当。

核心结论

  • 既往双特异性抗体暴露不 adversely 影响异基因造血干细胞移植的安全性,可能与改善疾病控制相关。

研究设计与样本

  • 国际回顾性研究,比较47例双特异性抗体暴露后首次异基因造血干细胞移植的复发/难治B细胞非霍奇金淋巴瘤成人患者与101例历史未暴露队列。
  • 采用逆概率治疗加权(IPTW)和倾向性评分匹配(PSM)处理基线不平衡。

主要发现

  • 2年非复发死亡率在暴露组与未暴露组间无显著差异(IPTW:29.1% vs 31.4%,P=0.80;PSM:35.8% vs 27.9%,P=0.43)。
  • 累积复发率在IPTW分析中暴露组显著更低(7.4% vs 20.0%,P=0.01),PSM分析中未达显著(9.5% vs 23.4%,P=0.06)。
  • 大B细胞淋巴瘤亚组中累积复发率差异在IPTW(6.1% vs 21.1%,P=0.01)和PSM(9.2% vs 33.3%,P=0.03)中一致。
  • 大B细胞淋巴瘤亚组中无进展生存期在IPTW分析中显著改善(55.5% vs 36.6%,P=0.04),PSM分析中未显著(P=0.20)。
  • 总生存、移植物抗宿主病、无GVHD无复发生存和植入情况两组相当。

临床怎么用

  • 对于复发/难治B细胞非霍奇金淋巴瘤患者,既往双特异性抗体暴露不应被视为异基因造血干细胞移植的禁忌。
  • 双特异性抗体暴露后移植可能带来更好的疾病控制,尤其在大B细胞淋巴瘤患者中。

局限性

  • 回顾性研究设计,样本量有限(暴露组47例,未暴露组101例)。
  • 部分终点在PSM分析中未达统计学显著性,需前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Bispecific antibodies (BsAb) targeting CD20 and CD3 have shown efficacy for relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL), but their impact on outcomes following allogeneic hematopoietic cell transplantation (alloHCT) remains unclear. In this international, retrospective study, we compared outcomes of adult patients with R/R B-NHL undergoing first alloHCT after BsAb exposure (n = 47) versus a historical BsAb-naïve cohort (n = 101). Baseline imbalances were addressed using inverse probability of treatment weighting (IPTW) and propensity score matching (PSM). The primary end point was nonrelapse mortality (NRM); secondary end points included overall survival (OS), progression-free survival (PFS), cumulative incidence of relapse (CIR), graft-versus-host disease (GVHD), engraftment, and GVHD/relapse-free survival (GRFS). In the overall cohort, 2-year NRM did not differ significantly between BsAb-exposed and BsAb-naïve groups (IPTW: 29.1% vs 31.4%, P = 0.80; PSM: 35.8% vs. 27.9%, P = 0.43). CIR was significantly lower in BsAb-exposed patients after IPTW (7.4% vs 20.0%, P = 0.01), but not in PSM (9.5% vs 23.4%, P = 0.06). OS, GVHD, GRFS, and engraftment were comparable. In a prespecified subanalysis limited to large B-cell lymphomas, CIR differences were consistent across IPTW (6.1% vs 21.1%, P = 0.01) and PSM (9.2% vs 33.3%, P = 0.03), reinforcing a potential benefit of prior BsAb therapy. A significant improvement in PFS was observed in this subgroup with IPTW (55.5% vs 36.6%; P = 0.04), but not in PSM (P = 0.20). Prior BsAb exposure does not adversely impact alloHCT safety and may be associated with improved disease control. Prospective studies are warranted to define optimal sequencing in this high-risk population.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Peña M, Losi G, Navarro V, et al. Allogeneic HCT as consolidation in B-cell lymphomas after exposure to bispecific antibodies: a GETH-TC study. Blood Adv. 2026. PMID: 41529227. doi:10.1182/bloodadvances.2025018152

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。